Join
Live feed
·
PRReleasevia Quantisnow
Ventyx Biosciences Inc. logo

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

ByQuantisnow·Wall Street's wire, on your screen.
VTYX· Ventyx Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTYX (Ventyx Biosciences Inc.) and more on Quantisnow.